MX2007006927A - Combinacion de inhibidor de tirosina cinasa y her-2/neu para terapia de cancer. - Google Patents
Combinacion de inhibidor de tirosina cinasa y her-2/neu para terapia de cancer.Info
- Publication number
- MX2007006927A MX2007006927A MX2007006927A MX2007006927A MX2007006927A MX 2007006927 A MX2007006927 A MX 2007006927A MX 2007006927 A MX2007006927 A MX 2007006927A MX 2007006927 A MX2007006927 A MX 2007006927A MX 2007006927 A MX2007006927 A MX 2007006927A
- Authority
- MX
- Mexico
- Prior art keywords
- neu
- combination
- tyrosine kinase
- kinase inhibitor
- cancer therapy
- Prior art date
Links
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 title 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical class C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describe un metodo para tratar el cancer que comprende la administracion de una 4-quinazolinamina y una vacuna que trata la molecula HER-2/neu, asi como una combinacion farmaceutica que comprende 4-quinazolinaminas y una vacuna que trata la molecula HER-2/neu.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0427131.8A GB0427131D0 (en) | 2004-12-10 | 2004-12-10 | Novel combination |
PCT/EP2005/013409 WO2006061253A2 (en) | 2004-12-10 | 2005-12-08 | Combination of tyrosine kinase inhibitor and her-2/neu for cancer therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2007006927A true MX2007006927A (es) | 2007-06-26 |
Family
ID=34073534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007006927A MX2007006927A (es) | 2004-12-10 | 2005-12-08 | Combinacion de inhibidor de tirosina cinasa y her-2/neu para terapia de cancer. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20100028414A1 (es) |
EP (1) | EP1824509A2 (es) |
JP (1) | JP2008523017A (es) |
KR (1) | KR20070098857A (es) |
CN (1) | CN101115499A (es) |
AU (1) | AU2005313439A1 (es) |
BR (1) | BRPI0518619A2 (es) |
CA (1) | CA2589981A1 (es) |
GB (1) | GB0427131D0 (es) |
IL (1) | IL183448A0 (es) |
MA (1) | MA29133B1 (es) |
MX (1) | MX2007006927A (es) |
NO (1) | NO20072668L (es) |
RU (1) | RU2007120462A (es) |
WO (1) | WO2006061253A2 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7972602B2 (en) * | 2006-08-11 | 2011-07-05 | Dendreon Corporation | Promiscuous HER-2/Neu CD4 T cell epitopes |
WO2008088861A2 (en) * | 2007-01-18 | 2008-07-24 | University Of Southern California | Gene polymorphisms predictive for dual tki therapy |
US8623592B2 (en) * | 2008-08-15 | 2014-01-07 | Merrimack Pharmaceuticals, Inc. | Methods and systems for predicting response of cells to a therapeutic agent |
EP2328613A1 (en) * | 2008-08-28 | 2011-06-08 | GlaxoSmithKline Biologicals S.A. | Vaccine |
WO2012018260A1 (en) * | 2010-08-05 | 2012-02-09 | Universiteit Utrecht Holding B.V. | Epidermal growth factor receptor targeted immune therapy |
CN107531320B (zh) * | 2015-03-19 | 2021-12-21 | 威罗门飞行公司 | 抗机械冲击印刷电路板(pcb)的安装系统 |
RU2603943C1 (ru) * | 2016-02-01 | 2016-12-10 | Индивидуальный предприниматель Михайлов Олег Ростиславович | КРИСТАЛЛИЧЕСКАЯ γ-МОДИФИКАЦИЯ N-{3-ХЛОР-4-[(3-ФТОРБЕНЗИЛ)ОКСИ] ФЕНИЛ}-6-[5-({[2-(МЕТАНСУЛЬФОНИЛ)ЭТИЛ]АМИНО}МЕТИЛ)-2-ФУРИЛ]-4-ХИНАЗОЛИНАМИНА БИС (4-МЕТИЛБЕНЗОЛСУЛЬФОНАТА) МОНОГИДРАТА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЁ ОСНОВЕ |
US20210121518A1 (en) * | 2018-02-15 | 2021-04-29 | Board of Supervisors for the University of Louisiana System | Her2-targeted peptidomimetics grafted onto multicyclic peptide scaffolds and methods and uses |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4436727A (en) * | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4866034A (en) * | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
US4877611A (en) * | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
US4912094B1 (en) * | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5759551A (en) * | 1993-04-27 | 1998-06-02 | United Biomedical, Inc. | Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines |
US5856462A (en) * | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
GB9717953D0 (en) * | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
GB9800569D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
IL144371A0 (en) * | 1999-01-29 | 2002-05-23 | Corixa Corp | Her-2/neu fusion proteins |
TW200914443A (en) * | 2000-06-30 | 2009-04-01 | Glaxo Group Ltd | Process for preparing substituted quinazolinyl furanaldehyde |
ES2236481T3 (es) * | 2001-01-16 | 2005-07-16 | Glaxo Group Limited | Combinacion farmaceutica que contiene una 4-quinazolinamina y paclitaxel, carboplatino o vinorelbina para el tratamiento de cancer. |
US20060204966A1 (en) * | 2003-08-01 | 2006-09-14 | Spector Neil L | Treatment of cancers expressing p95 erbb2 |
KR20080014144A (ko) * | 2003-08-18 | 2008-02-13 | 화이자 프로덕츠 인크. | erbB2 항암제에 대한 투약 스케쥴 |
-
2004
- 2004-12-10 GB GBGB0427131.8A patent/GB0427131D0/en not_active Ceased
-
2005
- 2005-12-08 AU AU2005313439A patent/AU2005313439A1/en not_active Abandoned
- 2005-12-08 RU RU2007120462/14A patent/RU2007120462A/ru not_active Application Discontinuation
- 2005-12-08 KR KR1020077015752A patent/KR20070098857A/ko not_active Application Discontinuation
- 2005-12-08 US US11/720,621 patent/US20100028414A1/en not_active Abandoned
- 2005-12-08 BR BRPI0518619-6A patent/BRPI0518619A2/pt not_active IP Right Cessation
- 2005-12-08 CA CA002589981A patent/CA2589981A1/en not_active Abandoned
- 2005-12-08 JP JP2007544843A patent/JP2008523017A/ja active Pending
- 2005-12-08 WO PCT/EP2005/013409 patent/WO2006061253A2/en active Application Filing
- 2005-12-08 MX MX2007006927A patent/MX2007006927A/es not_active Application Discontinuation
- 2005-12-08 EP EP05825761A patent/EP1824509A2/en not_active Ceased
- 2005-12-08 CN CNA2005800479161A patent/CN101115499A/zh active Pending
-
2007
- 2007-05-25 NO NO20072668A patent/NO20072668L/no not_active Application Discontinuation
- 2007-05-28 IL IL183448A patent/IL183448A0/en unknown
- 2007-06-18 MA MA30001A patent/MA29133B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
IL183448A0 (en) | 2007-09-20 |
NO20072668L (no) | 2007-09-04 |
RU2007120462A (ru) | 2009-01-20 |
AU2005313439A1 (en) | 2006-06-15 |
WO2006061253A3 (en) | 2006-11-16 |
CN101115499A (zh) | 2008-01-30 |
BRPI0518619A2 (pt) | 2008-11-25 |
KR20070098857A (ko) | 2007-10-05 |
EP1824509A2 (en) | 2007-08-29 |
WO2006061253A2 (en) | 2006-06-15 |
MA29133B1 (fr) | 2008-01-02 |
CA2589981A1 (en) | 2006-06-15 |
JP2008523017A (ja) | 2008-07-03 |
US20100028414A1 (en) | 2010-02-04 |
GB0427131D0 (en) | 2005-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2007006927A (es) | Combinacion de inhibidor de tirosina cinasa y her-2/neu para terapia de cancer. | |
NO20022065L (no) | Terapeutisk anvendelse | |
WO2007075554A3 (en) | Combination of igfr inhibitor and anti-cancer agent | |
EA200501849A1 (ru) | Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ | |
MY141739A (en) | Substituted quinazoline derivatives as inhibitors of aurora kinases | |
HK1087613A1 (en) | Quinazoline derivatives and their use in the treatment of cancer | |
IL175158A0 (en) | Tocopherol-modified therapeutic drug compounds | |
MY141220A (en) | Pyrazole derivatives as inhibitors of receptor tyrosine kinases | |
MXPA03010121A (es) | Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales. | |
MX2007004549A (es) | Tratamiento combinado con bortezomib y un inhibidor de cinasa del receptor del factor de crecimiento epidermico. | |
IL154949A0 (en) | Imidazole derivatives as raf kinase inhibitors | |
TW200500355A (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
MXPA05012155A (es) | Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades. | |
MXPA03007837A (es) | Composiciones para suministrar bisfosfonatos. | |
DK1519724T3 (da) | Fredericamycin-derivater som lægemidler til behandling af tumorer | |
DK1165108T3 (da) | Anvendelse af et ekstrakt af Serenoa repens til fremstilling af et lægemiddel til behandling af prostatacancer | |
MY138059A (en) | Use of ikb-kinase inhibitors in pain therapy | |
GB0121490D0 (en) | Ciompounds | |
WO2005105094A3 (en) | Cancer treatment method | |
WO2006110176A3 (en) | Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor | |
TNSN04015A1 (en) | Combination therapy for the treatment of cancer | |
TW200608959A (en) | Treatment with oxaliplatin and an egfr-inhibitor | |
AU2162202A (en) | Antitumor therapy comprising distamycin derivatives | |
GB0121494D0 (en) | Compounds | |
GEP201606538B (en) | Preoperative treatment of post operative pain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |